Back to search
FDAFDA · Food and drugs·Recall number D-0608-2025

Semaglutide, 2.5 mg/mL injection, 0.8 mL, Boothwyn Pharmacy

Published September 10, 2025 · Recall initiated: July 9, 2025

Summary

FDA records drug Class II recall D-0608-2025, published September 10, 2025 and initiated July 9, 2025. Recalling firm: Boothwyn Pharmacy LLC; Status: Ongoing; Reported quantity: 186 vials; Lot: 03202025@9 BUD 07/18/2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent Drug

What to do

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Boothwyn Pharmacy LLC
Distributor
U.S. Nationwide
Lot
03202025@9 BUD 07/18/2025
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Semaglutide, 2.5 mg/mL injection, 0.8 mL, Boothwyn Pharmacy recalled?

Yes. FDA published recall D-0608-2025 on September 10, 2025. Reported hazard: Subpotent Drug

What should I do if I have this product?

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit